[go: up one dir, main page]

HK1256412A1 - 基於變體的疾病診斷和追蹤 - Google Patents

基於變體的疾病診斷和追蹤

Info

Publication number
HK1256412A1
HK1256412A1 HK18115544.9A HK18115544A HK1256412A1 HK 1256412 A1 HK1256412 A1 HK 1256412A1 HK 18115544 A HK18115544 A HK 18115544A HK 1256412 A1 HK1256412 A1 HK 1256412A1
Authority
HK
Hong Kong
Prior art keywords
tracking
based disease
variant based
disease diagnostics
diagnostics
Prior art date
Application number
HK18115544.9A
Other languages
English (en)
Inventor
Claude Venn Oliver
Original Assignee
Grail Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grail Inc filed Critical Grail Inc
Publication of HK1256412A1 publication Critical patent/HK1256412A1/zh

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK18115544.9A 2016-01-22 2018-12-05 基於變體的疾病診斷和追蹤 HK1256412A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662286103P 2016-01-22 2016-01-22
PCT/US2017/014427 WO2017127742A1 (en) 2016-01-22 2017-01-20 Variant based disease diagnostics and tracking

Publications (1)

Publication Number Publication Date
HK1256412A1 true HK1256412A1 (zh) 2019-09-20

Family

ID=59360599

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115544.9A HK1256412A1 (zh) 2016-01-22 2018-12-05 基於變體的疾病診斷和追蹤

Country Status (8)

Country Link
US (2) US20170213008A1 (zh)
EP (1) EP3405574A4 (zh)
JP (3) JP2019509018A (zh)
CN (1) CN108603234A (zh)
AU (2) AU2017209330B2 (zh)
CA (1) CA3010418A1 (zh)
HK (1) HK1256412A1 (zh)
WO (1) WO2017127742A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4043584A1 (en) 2015-12-08 2022-08-17 Twinstrand Biosciences, Inc. Improved adapters, methods, and compositions for duplex sequencing
EP3552128A1 (en) 2016-12-08 2019-10-16 Life Technologies Corporation Methods for detecting mutation load from a tumor sample
US10699802B2 (en) 2017-10-09 2020-06-30 Strata Oncology, Inc. Microsatellite instability characterization
CA3083787A1 (en) 2017-12-01 2019-06-06 Personal Genome Diagnositics Inc. Process for microsatellite instability detection
CN112020563A (zh) * 2018-03-06 2020-12-01 癌症研究技术有限公司 变体检测的改进
CA3097146A1 (en) * 2018-04-16 2019-10-24 Memorial Sloan Kettering Cancer Center Systems and methods for detecting cancer via cfdna screening
EP3844755A1 (en) * 2018-08-28 2021-07-07 Life Technologies Corporation Methods for detecting mutation load from a tumor sample
WO2020047378A1 (en) * 2018-08-31 2020-03-05 Guardant Health, Inc. Microsatellite instability detection in cell-free dna
EP3850111A4 (en) * 2018-09-14 2022-06-29 Lexent Bio, Inc. Methods and systems for assessing microsatellite instability
WO2020102261A1 (en) * 2018-11-13 2020-05-22 Myriad Genetics, Inc. Methods and systems for somatic mutations and uses thereof
WO2020132151A1 (en) * 2018-12-19 2020-06-25 Grail, Inc. Cancer tissue source of origin prediction with multi-tier analysis of small variants in cell-free dna samples
AU2020364225B2 (en) * 2019-10-08 2023-10-19 Illumina, Inc. Fragment size characterization of cell-free DNA mutations from clonal hematopoiesis
EP3809414A1 (en) * 2019-10-15 2021-04-21 Koninklijke Philips N.V. Method and apparatus for assessing patient's response to therapy
US20210166813A1 (en) * 2019-11-27 2021-06-03 Grail, Inc. Systems and methods for evaluating longitudinal biological feature data
CN113684274B (zh) * 2020-05-18 2022-06-03 普瑞基准生物医药(苏州)有限公司 用于恶性女性生殖细胞肿瘤诊断和治疗试剂盒
CN111785324B (zh) * 2020-07-02 2021-02-02 深圳市海普洛斯生物科技有限公司 一种微卫星不稳定分析方法及装置
CN112086129B (zh) * 2020-09-23 2021-04-06 深圳吉因加医学检验实验室 预测肿瘤组织cfDNA的方法及系统
WO2022178337A1 (en) * 2021-02-19 2022-08-25 Tempus Labs, Inc. Longitudinal molecular diagnostics detect somatic reversion mutations
CN113096728B (zh) * 2021-06-10 2021-08-20 臻和(北京)生物科技有限公司 一种微小残余病灶的检测方法、装置、存储介质及设备
WO2023019110A1 (en) * 2021-08-10 2023-02-16 Foundation Medicine, Inc. Methods and systems for detection of reversion mutations from genomic profiling data
CN113990492B (zh) * 2021-11-15 2022-08-26 至本医疗科技（上海）有限公司 确定关于实体瘤微小残留病灶的检测参数的方法、设备和存储介质
CN116805510B (zh) * 2022-09-01 2024-07-19 杭州链康医学检验实验室有限公司 用于判断样本配对或污染的位点组合及其应用
CN115679000B (zh) * 2022-12-30 2023-03-21 臻和(北京)生物科技有限公司 微小残留病灶的检测方法、装置、设备和存储介质
KR20240177044A (ko) * 2023-06-19 2024-12-27 진스토리코리아 주식회사 Snp를 이용하여 유전자 종합 점수를 산출하는 시스템 및 snp를 이용하여 유전자 종합 점수를 산출하는 방법
WO2025007034A1 (en) * 2023-06-29 2025-01-02 Guardant Health, Inc. Methods for determining surveillance and therapy for diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513747C (en) * 2003-01-24 2017-03-07 University Of Utah Methods of predicting mortality risk by determining telomere length
BRPI0510266A (pt) * 2004-04-26 2007-10-30 Childrens Medical Center métodos para a detecção de uma doença ou distúrbio angiogênico em um indivìduo, para a detecção de cáncer em um indivìduo, para o tratamento de um indivìduo afetado com uma doença ou distúrbio angiogênico, para a determinação da probabilidade de eficácia de uma terapia anti-angiogênica, para a determinação da eficácia de uma terapia de teste na modulação dos nìveis de reguladores angiogênicos de plaqueta, para a criação de um registro ou perfil de plaqueta para uma doença ou distúrbio angiogênico e para a monitoração da eficácia de uma terapia em um indivìduo com uma doença ou distúrbio angiogênico
US20090298709A1 (en) * 2008-05-28 2009-12-03 Affymetrix, Inc. Assays for determining telomere length and repeated sequence copy number
WO2010018601A2 (en) * 2008-08-15 2010-02-18 Decode Genetics Ehf Genetic variants predictive of cancer risk
CA2826748C (en) * 2011-02-09 2020-08-04 Bio-Rad Laboratories, Inc. Method of detecting variations in copy number of a target nucleic acid
EP3736281A1 (en) * 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US20140364439A1 (en) * 2011-12-07 2014-12-11 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20140129152A1 (en) * 2012-08-29 2014-05-08 Michael Beer Methods, Systems and Devices Comprising Support Vector Machine for Regulatory Sequence Features
US20150073724A1 (en) * 2013-07-29 2015-03-12 Agilent Technologies, Inc Method for finding variants from targeted sequencing panels
JP2015035212A (ja) * 2013-07-29 2015-02-19 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ターゲットシークエンシングパネルから変異を見つける方法
US10597715B2 (en) * 2013-12-05 2020-03-24 Centrillion Technology Holdings Methods for sequencing nucleic acids
US20160002717A1 (en) * 2014-07-02 2016-01-07 Boreal Genomics, Inc. Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease

Also Published As

Publication number Publication date
AU2017209330A1 (en) 2018-07-19
WO2017127742A1 (en) 2017-07-27
CN108603234A (zh) 2018-09-28
JP2019509018A (ja) 2019-04-04
AU2023204105A1 (en) 2023-07-13
CA3010418A1 (en) 2017-07-27
EP3405574A4 (en) 2019-10-02
US20240331873A1 (en) 2024-10-03
AU2017209330B2 (en) 2023-05-04
JP2024009859A (ja) 2024-01-23
EP3405574A1 (en) 2018-11-28
US20170213008A1 (en) 2017-07-27
JP2022031683A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
HK1256412A1 (zh) 基於變體的疾病診斷和追蹤
IL283321A (en) Antibodies against muc16 and their uses
HK1254861A1 (zh) 抗lag3抗體及其用途
IL260678B (en) Systems and methods to improve diagnosis of diseases
HK1250238A1 (zh) 抗angptl8抗體及其用途
ZA201800536B (en) Il-8-binding antibodies and uses thereof
HK1256381A1 (zh) 抗pacap抗體及其用途
IL251837A0 (en) Anti-endoglin antibodies and their uses
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
PL3292154T3 (pl) Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
GB201712357D0 (en) Spetral imaging
GB201609712D0 (en) Disease targets and biomarkers
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途
GB2550826B (en) Tracking area configuration
IL267982A (en) diagnosis
GB201500875D0 (en) Antibodies for treatment and diagnosis
IL254245A0 (en) Imaging systems and methods
GB201504297D0 (en) Diagnosis
GB201607456D0 (en) Imaging unit
GB2542888B (en) Fingerprint imaging
GB2555564B (en) Scatter imaging
GB201621964D0 (en) Stroke diagnosis
GB201610207D0 (en) Samsaroon Physiological Analytics